Evolent Health price target raised to $44 from $33 at Piper Sandler

Piper Sandler analyst Jessica Tassan raised the firm’s price target on Evolent Health to $44 from $33 and keeps an Overweight rating on the shares. The analyst says a large total addressable market, "deep competitive moats," high visibility into profitable double-digit growth, a "compelling" catalyst path, upside to deal synergies and a discounted valuation make Evolent a top pick for fiscal 2023.